DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 2989-2996

  Gnyszka, Agnieszka ^a   Jastrzȩbski, Zenon ^a   Flis, Sylwia ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Cancer therapy; DNA methylation; DNMT inhibitors; Epigenetics; Review

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTIDINE DEAMINASE; DNA METHYLTRANSFERASE; GENOMIC DNA; ZEBULARINE;

CANCER INHIBITION; CANCER THERAPY; CELL DIFFERENTIATION; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; EPIGENETICS; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN;

CANCER THERAPY; DNA METHYLATION; DNMT INHIBITORS; EPIGENETICS; REVIEW;

AZA COMPOUNDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 84883306098     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Waddington CH: The epigenotype. Endeavour 1: 18-20, 1942.
2. Berger SL, Kouzarides T, Shiekhattar R and Shilatifard A: An operational definition of epigenetics. Genes Dev 23: 781-783, 2009.
3. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2: 4-11, 2005.
4. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
5. Reik W: Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425-432, 2007.
6. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, Leonhardt H: Trapped in action: Direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2: 751-756, 2005.
7. Suzuki MM and Bird A: DNA methylation landscapes: Provocative insights from epigenomics. Nat Rev Genet 9: 465-476, 2008.
8. Patai AV, Molnár B, Kalmár A, Schöller A, Tóth K and Tulassay Z: Role of DNA methylation in colorectal carcinogenesis. Dig Dis 30: 310-315, 2012.
9. Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet 9: 2395-2402, 2000.
10. Gros C, Fahy J, Halby L, Dufau I, Erdmann A, Gregoire JM, Ausseil F, Vispé S and Arimondo PB: DNA methylation inhibitors in cancer: Recent and future approaches. Biochimie 94: 2280-2296, 2012.
11. Sasai N and Defossez PA: Many paths to one goal? The proteins that recognize methylated DNA in eukaryotes. Int J Dev Biol 53: 323-334, 2009.
12. Prendergast GC and Ziff EB: Methylation-sensitive sequencespecific DNA binding by the c-Myc basic region. Science 251: 186-189, 1991.
13. Esteller M: Epigenetics in Cancer. N Engl J Med 358: 1148-1159, 2008.
14. Brueckner B and Lyko F: DNA methyltransferase inhibitors: Old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 25: 551-554, 2004.
15. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
16. Chik F, Szyf M and Rabbani SA: Role of epigenetics in cancer initiation and progression. Adv Exp Med Biol 720: 91-104, 2011.
17. Cowan LA, Talwar S and Yang AS: Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2: 71-86, 2010.
18. Leone G, Voso MT, Teofili L and Lübbert M: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 109: 89-102, 2003.
19. Yang X, Lay F, Han H and Jones PA: Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31: 536-546, 2010.
20. Santi DV, Norment A and Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81: 6993-6997, 1984.
21. Stresemann C and Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123: 8-13, 2008.
22. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA and Agbaria R: Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70: 121-133, 2005.
23. Billam M, Sobolewski MD and Davidson NE: Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 120: 581-592, 2010.
24. Champion Ch, Guianvarc'h D, Sénamaud-Beaufort C, Jurkowska RZ, Jeltsch A, Konger L, Arimondo PB and Guieysse-Peugeot AL: Mechanistic insights on the inhibition of C5 DNA methyltransferases by zebularine. PLoS One 5: e12388, 2010.
25. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC and Pazdur R: Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 15: 3604-3608, 2005.
26. Momparler RL: Pharmacology of 5-aza-2'-deoxycytidine (decitabine). Semin Hematol 42: 9-16, 2005.
27. Yoo CB, Cheng JC and Jones PA: Zebularine: A new drug for epigenetic therapy. Biochem Soc Trans 32: 910-912, 2004.
28. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ and Egorin MJ: Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 15: 3862-3868, 2005.
29. Stresemann C, Brueckner B, Musch T, Stopper H and Lyko F: Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-2800, 2006.
30. Qin T, Jelinek J, Si J, Shu J and Issa JP: Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 113: 659-667, 2009.
31. Yang X, Lay F, Han H and Jones PA: Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31: 536-546, 2010.
32. Cortez CC and Jones PA: Chromatin, cancer and drug therapies. Mutat Res 647: 44-51, 2008.
33. Jones PA and Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93, 1980.
34. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C and MacBeth KJ: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5: e9001, 2010.
35. Li LH, Olin EJ, Buskirk HH and Reineke LM: Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 30: 2760-2769, 1970.
36. Nieto M, Samper E, Fraga MF, González de Buitrago G, Esteller M and Serrano M: The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine. Oncogene 23: 735-743, 2004.
37. Schneider-Stock R, Diab-Assef M, Rohrbeck A, Foltzer- Jourdainne C, Boltze C, Hartig R, Schönfeld P, Roessner A and Gali-Muhtasib H: 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3A and induces apoptosis in HCT-116 colon cancer cells via GADD45- and p53-dependent mechanisms. J Pharmacol Exp Ther 312: 525-536, 2005.
38. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD and Robertson KD: DNA methylation inhibitor 5-aza-2'- deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28: 752-771, 2008.
39. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ and Hornby DP: Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321: 591-599, 2002.
40. Marquez VE, Eritja R, Kelley JA, Vanbemmel D and Christman JK: Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (zebularine) at the GCGC recognition domain. Ann NY Acad Sci 1002: 154-164, 2003.
41. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA and Selker EU: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409, 2003.
42. Lemaire M, Momparler LF, Bernstein ML, Marquez VE and Momparler RL: Enhancement of antineoplastic action of 5-aza- 2'-deoxycytidine by zebularine on L1210 leukemia. Anti-cancer Drug 16: 301-308, 2005.
43. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR and DeCoteau GF: Zebularine inhibits human acute myeloid leukaemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35: 263-273, 2007.
44. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH and Nephew KP: Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4: 1505-1514, 2005.
45. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE and Jones PA: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278, 2004.
46. Oka M, Meacham AM, Hamazaki T, Rodić N, Chang LJ and Terada N: De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'- deoxycytidine. Oncogene 24: 3091-3099, 2005.
47. Hurd PJ, Whitmarsh AJ, Baldwin GS, Kelly SM, Waltho JP, Connolly BA and Hornby DP: Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 286: 389-401, 1999.
48. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L and Mans DR: A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18: 83-91, 2000.
49. Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O Jr., Monego E, Rivoire W and Schwartsmann G: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25: 496-501, 2002.
50. Flis S, Gnyszka A, Misiewicz-Krzemińska I and Spł awiński J: Decytabine enhances cytotoxicity induced by oxaliplatin and 5- fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell Int 9: 1-10, 2009.
51. Vijayaraghavalu S, Dermawan JK, Cheriyath V and Labhasetwar V: Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm 10: 337-352, 2013.
52. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB and Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609, 2007.
53. Herranz M, Martín-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, Marquez V and Esteller M: The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 107: 1174-1177, 2006.
54. Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC and Jiang SW: DNA hypermethylation as a chemotherapy target. Cell Signal 23: 1082-1093, 2011.
55. Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ and Kim TY: Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med 85: 1137-1148, 2007.
56. Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV and Kanner SB: Epigenetic drug discovery: Targeting DNA methyltransferases. J Biomol Screen 17: 2-17, 2012.